Literature DB >> 10552977

New species-related MIC breakpoints for early detection of development of resistance among gram-negative bacteria in Swedish intensive care units.

H Hanberger1, L E Nilsson, B Claesson, A Kärnell, P Larsson, M Rylander, E Svensson, M Sörberg, L Sörén.   

Abstract

The frequency of decreased antibiotic susceptibility among 534 Gram-negative aerobic bacilli from patients admitted to intensive care units at eight hospitals in Sweden during 1997 was evaluated. MICs of cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem and piperacillin-tazobactam were determined using Etest. Reduced susceptibility (resistant and intermediate/indeterminate susceptible strains) was defined according to the MIC breakpoints of the British Society for Antimicrobial Chemotherapy (BSAC), the National Committee for Clinical Laboratory Standards (NCCLS) and the new species-related breakpoints of the Swedish Reference Group for Antibiotics (SRGA). The BSAC/NCCLS/SRGA breakpoints for susceptible category (mg/L) of Enterobacteriaceae are: cefepime, not available (NA)/8/0.5; ceftazidime, 2/8/2; ceftriaxone, NA/8/0.5; ciprofloxacin, 1/1/0.12; gentamicin, 1/4/2; imipenem, 4/4/1; and piperacillin-tazobactam, NA/16/16. The most frequently isolated organisms were Escherichia coli (n = 160; 30%), Klebsiella spp. (n = 84; 16%), Enterobacter spp. (n = 77; 14%), Pseudomonas aeruginosa (n = 64; 12%) andProteus spp. (n = 28; 5%). Decreased susceptibility among E. coliusing the BSAC/NCCLS/SRGA respective breakpoints (%) were: cefepime, NA/0/2; ceftazidime, 2/2/2; ceftriaxone, NA/1/2; ciprofloxacin, 2/2/8; gentamicin, 21/0/3; imipenem, 0/0/2; and piperacillin-tazobactam, NA/4/4. Corresponding levels of decreased susceptibility (%) among Klebsiellaspp. were: cefepime, NA/0/5; ceftazidime, 2/1/2; ceftriaxone, NA/1/10; ciprofloxacin, 4/4/19; gentamicin, 25/2/5; imipenem, 0/0/0; and piperacillin-tazobactam, NA/10/10; and among Enterobacter spp. were: cefepime, NA/1/19; ceftazidime, 30/29/30; ceftriaxone, NA/30/36; ciprofloxacin, 3/3/15; gentamicin,18/0/0; imipenem, 0/0/5; and piperacilllin-tazobactam, NA/27/27. In conclusion, the species-related SRGA breakpoints detected Gram-negative isolates with decreased susceptibility in comparison with the native population with higher frequency than did the NCCLS breakpoints. The BSAC breakpoints for susceptible organisms were similar to NCCLS for ciprofloxacin and imipenem, and similar to SRGA for ceftazidime but lower than both NCCLS and SRGA for gentamicin, causing a much higher frequency of decreased susceptibility to gentamicin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552977     DOI: 10.1093/jac/44.5.611

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Assumed versus approved breakpoints.

Authors:  D A Preston; M R Turnak
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Structure-activity relationships, kinetics, selectivity, and mechanistic studies of synthetic hydraphile channels in bacterial and mammalian cells.

Authors:  W Matthew Leevy; Seth T Gammon; Tatiana Levchenko; David D Daranciang; Oscar Murillo; Vladimir Torchilin; David Piwnica-Worms; James E Huettner; George W Gokel
Journal:  Org Biomol Chem       Date:  2005-08-26       Impact factor: 3.876

3.  Correlation of bilayer membrane cation transport and biological activity in alkyl-substituted lariat ethers.

Authors:  W Matthew Leevy; Michelle E Weber; Michael R Gokel; George B Hughes-Strange; David D Daranciang; Riccardo Ferdani; George W Gokel
Journal:  Org Biomol Chem       Date:  2005-04-11       Impact factor: 3.876

4.  Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Thomas Rimmelé; Jean-Charles Poupelin; Marie-Claude Saux; Dominique Chassard; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

Review 5.  Early diagnosis of resistant pathogens: how can it improve antimicrobial treatment?

Authors:  Sanjay Bhattacharya
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.